Customers can potentially use Gen9’s technology to more efficiently make everything from fabrics and chemicals to drugs and renewable fuels.
According to Gen9, methods using its technology are more cost-effective than traditional methods.
Headquartered in California, Agilent is a $6.9 billion company focused on chemical analysis, life sciences, diagnostics, electronics, and communications.
In a press release, Agilent said its partnership with Gen9 complements Agilent’s existing investments in synthetic biology and gene synthesis.
Agilent is taking an equity stake in Gen9.